N
Google TrendGREEN CARD (500+) — Vance says Microsoft replaced laid-off workers with foreign hires. Here’s what the visa data shows
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:green card500+power outage near me10000+sony playstation1000+india2000+loki100+hubert hurkacz200+will shipley100+anthony mackie100+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "NextPoint Therapeutics An" (30 stories)

Top Headline Story

NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors
Lead StoryBusiness Wireworld
Feb 9

NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors

<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxPSG1pdXRUWmJxSTNqMW8zS2hOM3pOMXpDR2xqVkRtZ0ljeEpfekNfbTlwYURkVjgtNnhFeVBpYmZGWnlrTml1RG5mQW5oWWFrbEpSeGJNUGhQSEx6V0g4RFR5ckxlWlQ0WWlSQkd1T1hjMGFaNlRMU2V1OElESDk2Vnl2bk1zTldhTU1nZW0zRFlCR0xMQ1UyOVZ2RWtnM2xCMmVCTlhvcEVneUF6azdjRWkyQmdkTl81cXYyaXRScDlOSElLNmpQWjQxQ0hmb2NTMm0zVDBfMjlJb1R5dlJWbThlaG81SWxpbXc0N0U4dUdDbUJIRXlZRGJMV2xQaFd5YU9iRjRHUG5rOGE1UG9z?oc=5" target="_blank">NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+22m ago

green card

Vance says Microsoft replaced laid-off workers with foreign hires. Here’s what the visa data shows

Filter stories
10000+22m ago

power outage near me

LIVE | Atlanta weather: Power outages, tree damage remain as storm threat moves east

Filter stories
1000+22m ago

sony playstation

PS2 Discs Now Load on Jailbroken PS5 Consoles Through PS5SX2 Emulator

Filter stories
2000+22m ago

india

CJP Protest Live: 'Modi, as PM, is embarrassment to India' - Dipke's 1st reaction after being released

Filter stories

Search Results for "NextPoint Therapeutics An"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
NextPoint Therapeutics Introduces NPX372, a Novel T Cell Engager Targeting B7-H7 Axis in Solid Tumors
BioPharma APACgeneral

NextPoint Therapeutics Introduces NPX372, a Novel T Cell Engager Targeting B7-H7 Axis in Solid Tumors

<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxOV2JzNjBwRkc5aTVkZU8tWDR1bVItNEt3Z3dOWlBqT010Y2dSVWNkcGlYMlJTaThCeml5bTBfMWlBcGRScm9xbGF0dUgwRXBfX19zYWRrMElfaktRVjJBZWhNMnJIS3Z1anlvV3JzelJHX2ZSLW5wbVphd2xaVkd3S0RMVHhBMnBPc1cyM09OWGhYQWRFNjVhTFZMQmhvYmJYQzZpYW1pX2FYbWxRaW9ISW1OdnBGTlk0bjBlcE5IME8yNnJLOU05S2s4dDFweEIwUWpnTGQ1V3VGWktqQ0pSR2V3?oc=5" target="_blank">NextPoint Therapeutics Introduces NPX372, a Novel T Cell Engager Targeting B7-H7 Axis in Solid Tumors</a>  <font color="#6f6f6f">BioPharma APAC</font>

Read Full StoryMore like this
NextPoint Therapeutics
The Pharma Lettergeneral

NextPoint Therapeutics

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE8yeW5fb0szc0dCamdTQVFsaXRFSmczQ0tpM1EtOVJQVTViZE5JVS1tZk4wNE1Vc3NnLWV3ZEt0UEVSQ0FxaEdfMVRDd09GN1p2dEFJZzRMXzNCSjE3N2phaXdaSzRWSDlLS1NHMjRDRDJlbHl2eDVR?oc=5" target="_blank">NextPoint Therapeutics</a>  <font color="#6f6f6f">The Pharma Letter</font>

Read Full StoryMore like this
NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management
Business Wireworld

NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management

<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxNNjZsWEVwQURxRmNuVktyS0hwa3dLUmwyMWdvQkg2Z1ItTmNLOUFBNmxWVTdvSmhqUmpVdzdCZ3RHcDRXcnZCemVCcmZkR0Nod2Rac1k1aWQwQk1kTl9kUnF1SGRraFk4Y3d6Q3psNUptOEQwQzVxWXM1ZDFxWlZfdWlsdVNmUWk4WTBlX2Vjb0dkaThLVUQyNFVqOFNHUERpZFd2WVB5R0ZsdTRWcDZWLVk0d3ctczh0VzdweUpPWG1qRlVuZFZHcWthd01fS3V0OEJzRlVCdE8xSFZoU01uNWd6VVZwNHpkZzRBRjFYbkxRN0tuemc?oc=5" target="_blank">NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
FDA accept NextPoint Therapeutics IND for HHLA2 targeting mAb
Pharmaceutical Technologygeneral

FDA accept NextPoint Therapeutics IND for HHLA2 targeting mAb

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQOTFsRWR4REMtOERfYl9MR1d0SHlydjNvOW94MVlkal8ybDBlS0l3cU9ZTG11V09zLWstX1Y1UjJiMk5DYVdQVFRZOVZXNFJ0UVBxOHBvOFM4UF9ybXVaYUgxdWVWbEJ5TVRmNWRlYnFWeXlMYUtxZ1c1OGxkdlRENFctYWE5NGtIOHFHekxyUDh1TWhpVlFvNWJmT21fVGJVa2NLU3FhUG1fQ0dVVUE?oc=5" target="_blank">FDA accept NextPoint Therapeutics IND for HHLA2 targeting mAb</a>  <font color="#6f6f6f">Pharmaceutical Technology</font>

Read Full StoryMore like this
Eisai's U.S. CEO hired to lead Cambridge cancer biotech
The Business Journalstech

Eisai's U.S. CEO hired to lead Cambridge cancer biotech

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE9OVDUxc01ZbWx3dFBuZTk0WjVtUGl6ZG9IaTBST3Bld3k3cm4zSkhPakdDeVM3d0daekZqSlE4UmxLNENNZXVlYzBLZnBnTTZQRzI4cVhlV2tDQ1h4R3E5VE14Q1JSc0lhM3hDeDVwN2dyUExKdmV2MzA0NmI1Zw?oc=5" target="_blank">Eisai's U.S. CEO hired to lead Cambridge cancer biotech</a>  <font color="#6f6f6f">The Business Journals</font>

Read Full StoryMore like this
Chutes & Ladders—Ex-Eisai leader Ivan Cheung tapped to be new CEO of NextPoint
Fierce Biotechtech

Chutes & Ladders—Ex-Eisai leader Ivan Cheung tapped to be new CEO of NextPoint

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNMWNGM1c3MVVPQ01KajlScVVMYnBxa25hRDZ0U2FQQnhJLUlxUWRrcC1yWm1sTXF1SWZXN3hLNi1uZjRodUdEV18tZ094UEdlci1PUHVWVFFZTEJxUW02NTY0WTRtYy11VWNya0RiQ3hpYVdqSV8zVzdKOFFZTWNIbUZJS0VzNTVZMTVZY2NxZHJDcG5zaTRwaTBoNkd4cVFaNUFiUHdB?oc=5" target="_blank">Chutes & Ladders—Ex-Eisai leader Ivan Cheung tapped to be new CEO of NextPoint</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Ivan Cheung
Time Magazineworld

Ivan Cheung

<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE80Vm5UT2cyRWZ3Yk5ZR1BDeXl3Sk1rVWp2U2s3QWpvZTBGbVpkb2NUSEg0Xy1pSFV4NlJYTjdjUUNHQ0w4UzVzM3lFVjV0enJSZG93N3JnY1UtMkZNbFlqRjJfemlNSFdZaXhqdUdwX3haQQ?oc=5" target="_blank">Ivan Cheung</a>  <font color="#6f6f6f">Time Magazine</font>

Read Full StoryMore like this
NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno-Oncology Programs:
Sage Journalsworld

NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno-Oncology Programs:

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxOdlBXaDNLdmVtdkpsMXZLN2RzUE1wUEc2LWU3azhXdE5rcTRTY2VWMDY4SUpPNGI1YXZocGpuY0MxWTRILUt3SUFNY0QwaVRYbWp5ckI1ZVMtM2VXSWlnMGdlNnBKNjFXaWN4Z2NxWHl1b2wyWllTWldoaHJmczcxTVBtVTdGbkhHNy1RQw?oc=5" target="_blank">NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno-Oncology Programs:</a>  <font color="#6f6f6f">Sage Journals</font>

Read Full StoryMore like this
Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an asset
Endpoints Newsgeneral

Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an asset

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOUXBZM2tzRGpvUlhmakFQekh4aFVac1p2aWlTVmFPcVhZdlQxYWp4N2MzaUhMWHZsTmZzSDJJQ09xanZHM3YwTmhkb3lfdUJrS2QyUGwzLWhoQU9xZkg1YnVGVnUtQzNZbDU0SUFIalVWOVlUQUtEX08tMnpiRlJERDkxZmhEUzh2TG8xSVBWcnVrZnZzSGx6aUdCQ21tTmlwb3VuSXhiaw?oc=5" target="_blank">Organon stops work on drug once viewed as ‘game-changing’; NextPoint culls an asset</a>  <font color="#6f6f6f">Endpoints News</font>

Read Full StoryMore like this
NPX887 being explored in HHLA2+ solid tumors, including RCC
Urology Timesgeneral

NPX887 being explored in HHLA2+ solid tumors, including RCC

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQQkhpUWRCcDVGLWNuVnBSWWpMQWh3cUxYQXdraWp2S1JrR1BGWVdBWDByTmZzdDlsUWtQb1dINTZjMFFUSTZ1cjFsNUNCYVB3bEFOTUlaU1RtQmNaNkdJc1VvNjFzaG15MHZNU2stdFZMY1FHclVOclQyOUFtSlRuRUJpeGRnUW9vMVpTVTA3dUNiTWFmUWc?oc=5" target="_blank">NPX887 being explored in HHLA2+ solid tumors, including RCC</a>  <font color="#6f6f6f">Urology Times</font>

Read Full StoryMore like this
People
Naturegeneral

People

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE0zTUJSb1EzOFZSQXRkWWN4cFh3X0tXZEgwNzliWGRnSEg4OGFYSTNLSHZDNWdRQThsXzBzRjlNN0xGUTdsaGdwWmpSWGE2bWpvZ3dVUUdUaWFSb2hLcUFZ?oc=5" target="_blank">People</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025
Business Wiregeneral

NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025

<a href="https://news.google.com/rss/articles/CBMisgJBVV95cUxORlVKeklUSDJuTWo2WmtSNWxSeE1tdzFaVUZfYU5pS1JBNkJhT0laMmFQdDlHMHBDb2REdEw1cGJrNk1OU1Z1RlRHaV9hVFZRU2tQcWk1bVRWV0tndHBQWkcxZDVPY1hTWTNRaU82OWNtWHJEZ2pCTUlnNVEwYTJwQXV4aERBeXVwTTFUOGJ4cWJtX05aZENwaUdRdW5qOUN1VlZ6aFNETDVKajZCSlFUQ2JRMEltWkRwT3ZKN1hlXzdXVDVUektqRGx5Wm9uR0ZjR2dwMng1aUNKNXUzZUI3bllKM1YwZmtRZW1oWkRjRUhCUWVLZnYwTUlsbkhnUURYSEVPV00xOFVCN3BQeFI4a0w4LXRNTDVIbEFkOXNGQVFiazltSDlCY0Jwd0l1T2Y4LVE?oc=5" target="_blank">NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Sanofi tops off venture arm, bringing fund to $750M
BioPharma Diveworld

Sanofi tops off venture arm, bringing fund to $750M

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQekxyeGo3aVV4cEdKdTRXYUdrdXlzeWlRVVZseUhDU0FDQ1Rjb05SRGxkVGF1QWVMMVdRdm1yMU1Fa1RsZmstVjdGZTlpM3NUbEo1eHROQ3Bhdmp5LVdBMTVqYTNldVJuX3RTQi10MkJ1c1NMdWt1QTQ2Q0h3WDEyTkRXQWdaUmMwd0Z6R2dn?oc=5" target="_blank">Sanofi tops off venture arm, bringing fund to $750M</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors
PR Newswireworld

Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors

<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxPUzl5LTZRc2YtNmhwMmZjUjlYcWVmaVJDNGg3WVdHNndFMTc4Q2xLY2tuY2duRG9FVURuVWhYaF9DcjVMM3FyVnlSbExCS2x4V0ZXMnZDNm1hckR2LVBRb2xTV3NpOVpIYklUX2kzcENRMXJ0VG5Od180MWFBUUFVaDJMZklsdDRKbkRycWhvLXBRTG9Pa3ZfdEtvRTg2M2Vsb1RjT1pQdHJKQTAyaHRVTzNvbVZScjRTOFNaMFRUM0dqdHNhSzFfSUFSQVBRbkw4NWVKb2FaWFNSajd4cFRkZGNXNVVLdzZJbExXTGVBYXktOXk5Q3JBa2lxX2dqUmM?oc=5" target="_blank">Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
After Eisai retirement, Ivan Cheung is back to lead Massachusetts biotech
Fierce Biotechtech

After Eisai retirement, Ivan Cheung is back to lead Massachusetts biotech

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPYm5fQjd5QTZWSVRERjBDTlE0dmdiVzZpbGZtMEVHY2xTc1VneGlWRkJJTGpxOTBVY3MwQVBrWTdXYUNBVXlvM1hjNDMxR2NSV1RKTnlIZGpxLU5KaVlWbS1rd0hGNnlHTXFnWWxFR2tJZG1pM0Q4N1ZWdjIxU2ltTFgwQU5od2RRN3NGNmt0WWp0U2ZCNTI5YWduLUpSdUo4UDJzZlhuNA?oc=5" target="_blank">After Eisai retirement, Ivan Cheung is back to lead Massachusetts biotech</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
NextPoint Therapeutics Appoints Ivan Cheung as Chief Executive Officer
Business Wireworld

NextPoint Therapeutics Appoints Ivan Cheung as Chief Executive Officer

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOQ3hVRkJSOW5NQzFYcTQySXBCOFotVkNNcW0ySmQ1bGdxbkh6ZWMxamdOaHZVNnd4SXBaRTdIa3IwVUZQbVF0X2dUT3lVaDZhdDNPRmk3eWJkNFZjS3Zlek03V2hyWVZUSUdWelc1Q29sZWIwZHk0VHI5X3RIZ1NDa19EREt5LUF6WHprZS1vVUxjeHN6Y3cwNGdzMlZqcE5TUDhsLUxxMktyYUdtZjdERXpJQ21TbUFZSzdNeHlPeEhTcnBPVFE?oc=5" target="_blank">NextPoint Therapeutics Appoints Ivan Cheung as Chief Executive Officer</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight
PR Newswiretech

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

<a href="https://news.google.com/rss/articles/CBMiqgJBVV95cUxOYXM2QTdfbmJwVURFUnBPWXp0REUyblpQNXVXQ1NrY2IwVjdlQzFGaGhmcmZiclZoU0RBQzU0YV9UNmltUVRMX0ZHMEFhU3FzemVjQ1FrcmZ6YllSdmpqM3ROa19fQU1HTzc3SHBBQmFNYXgwaEdPZUNSX3I3RHd0N040MHRiSG95THF6M2FtMDhwQUxSNHhWQWpJNDZvdW9tLU5fT2k3UmQ2MC1kYXZ4ZkVPcC1lMlhHWlhWaEtKOG9HYjFTeFJvdzk2djd1RjVTQUR3LU1sclEwSzJiYUFBN3F3aG1tbXkzckFiT2xzV2VfQjJEY2tNRy02dEp3elFYQmg5Njk0ZThfMEs4eEhYaDhXMFRqVWd2VXdjMXZER0JQVXVVY0VrNGpn?oc=5" target="_blank">Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Women Leadership in Immuno-Oncology Annual Profile Series: 2025 Edition
Fierce Biotechworld

Women Leadership in Immuno-Oncology Annual Profile Series: 2025 Edition

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOVnJSRWVoOWcyN1NMRjNRZUM2b21PRS05aGJpQXNCNnV1Uk9GeHBNVF9MTWg5LTNwdTZmTkdXTjhoSF9aU0doajZBXzVXZ0F0NElSSDhWM3ktSTZOSkZYSFNGUktzWU53Yk1YZ2tiRmRTVTMwdU5pVGNlV1lxdDFhQW4yTzZoWFhlMUJSZ0ViRzRUa1pLaVZ2Qnd1YUx6UTNJWU5yUjdLajNqYmJXaS1vUDgzTDNpTGZnUXEwQTB3?oc=5" target="_blank">Women Leadership in Immuno-Oncology Annual Profile Series: 2025 Edition</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Ensuring success in oncology clinical trials
Clinical Trials Arenageneral

Ensuring success in oncology clinical trials

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQN1EzYUg3R1hES19EalFFWm1zWm5XemM5YTFpUUZrUC1oWGNHQ1JtV3hZcE9vYTh5QkZYVnIwTU4yNlM3N0pJNlRJWUdnYnBqbVRYZ3dvNkx2U0dJd3B1dDdiRmtqcTZCZUVaM2tZSEFzaG1xakI0WkdvTEY0RDRtZ0Y4LXk3Nm9uaE1WeHlxQQ?oc=5" target="_blank">Ensuring success in oncology clinical trials</a>  <font color="#6f6f6f">Clinical Trials Arena</font>

Read Full StoryMore like this
Chutes & Ladders—Hardy replaces BioMarin’s commercial chief in first big move as CEO
Fierce Biotechgeneral

Chutes & Ladders—Hardy replaces BioMarin’s commercial chief in first big move as CEO

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQOGtZbG00N1Y4cGVCcXR6NEpFY0VqU0h4ZGpRQ3FadGpXOFdSeXZ1UzYtNXF2ZlpGd1BMaGRWNFpoM0lxRWtlS0xEb2szcDdEa25FNTVNNDlNRTlzREJJcjlPeEI3dGl2TXY1THBpV3I5SlFWeU9vdGVQYjM0T3lmMXNMcE45QXlDSXc2WjBUeTJUbjhmdnRJS1huVTBrdlBpX2hFbHVoQ2szX0RpNklvazJ6SQ?oc=5" target="_blank">Chutes & Ladders—Hardy replaces BioMarin’s commercial chief in first big move as CEO</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M
Fierce Biotechtech

Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxONjI2THYyOU9rbVhMMDRXU1JWNF9zcjRaT0R2TXR3SU5iQTktN1FYTlY1YzQzSkstRVFGZGxsOWg1RThVWENZTkRmemYyMEhBZzZFWUJZZ2h1YVJzN1NKaVpBSmMzWEU0TXlUbVhaZ0JtLTZDZmxiM1JEU1dBcU1PMg?oc=5" target="_blank">Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Aera Therapeutics Appoints Paul Conrad Chief Business and Financial Officer
Contract Pharmageneral

Aera Therapeutics Appoints Paul Conrad Chief Business and Financial Officer

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNX3ZfOUF1SV9odkQ5X1gteldKYVNQZXc4MHdvSUtZZzU5SURON2RYZHQ2LXo1Q003VEZZeFBXX2VoaEtlVXdrRzBxTTdfRmxESWdjSkU3TjU0ZERpU245c2xOcGRTWVNYamNfVF9nc2Q2VkZTZjl2YXA5eF80VUdfNjhrdFF3SjJqbUQ3R1FrM3JJUVdoNnhEUTI2WkZ0RkhqTDcyUm5fa1NKaXVpWXpWZEpBTy1DUHF6bG9oLWtn?oc=5" target="_blank">Aera Therapeutics Appoints Paul Conrad Chief Business and Financial Officer</a>  <font color="#6f6f6f">Contract Pharma</font>

Read Full StoryMore like this
Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight
PR Newswireworld

Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight

<a href="https://news.google.com/rss/articles/CBMinwJBVV95cUxOdVlhOFhDYnpBRGh4WlhFWG93ZHdmak5FZDVRVC1qWER1YlFhbnQ5TThBM0Y5ZjJaaExucGI2LVNsSmRUMDQ3cVBHT211N1JHVXNBRklDUTR1VjdITWkxSTA5OXNTMkZ2S3hnVDBMNHJYamp2Ri1UcHhBRlBLUWNxLXFMeHRlXzFpOXpkRzF4NlZWYlBGS0xqaGlHSlMzMkRFcG1tRjd4aU5sOE5TUWJvdklNd0F5YmZIMU91Tng5X0F3UlJESVI1M0tDaUFid2c1MjlhMlFiTHNGaUViTkN3b01pM2J4cndGY0NueG9VTTl0bGtmWF9KcEpZOVlodHZQWE5FbW1aNDBzTTNZTVNWTWpWZjhVM00zcHZIUV9sTQ?oc=5" target="_blank">Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Sanofi swells venture fund to $750m
Global Venturingworld

Sanofi swells venture fund to $750m

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE1rS0dKcE1VX2ZubnJGcVZKWWpQYWQ3N19yb05ucWNneVNLSV8yN1pLOUdXZDF0bzJXVkUyNkRpd3BtbG1CcjR4SkY0WFFWbU1DWllnbDZtSFZNMGluT0R1QWFrUEdCMTBJLW5FVFlqdEFKaGRzYnA4VQ?oc=5" target="_blank">Sanofi swells venture fund to $750m</a>  <font color="#6f6f6f">Global Venturing</font>

Read Full StoryMore like this
Sanofi pumps $750M into VC unit to push deeper into biotech investing
Fierce Biotechtech

Sanofi pumps $750M into VC unit to push deeper into biotech investing

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPMFlVMThTWmV3Wnh6U1dmZ1NGXy1FNzBBNzRrSVlPNENjcFNzWEw1cnF2X1liZzllWkplbFV6T1hLVjFXQmpEYjBNWmtZLTRPb1MxZGZRZ2FVM0ZMa0Y3bGZRcGVIbk9YZVJ4dl9HUXpKc1JrYmpBNW9XWHJ5UUo3ZU5pTEM4YnJhMTFPOFVrUVNDeXlReUUwQw?oc=5" target="_blank">Sanofi pumps $750M into VC unit to push deeper into biotech investing</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
LabCentral 238 Opens with Focus on Scale-Up Bio-Manufacturing
PR Newswiregeneral

LabCentral 238 Opens with Focus on Scale-Up Bio-Manufacturing

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQTVloLVFzWnUtMzRpNGY0RzliVHcwUzFtdGR2WEVoOHhGeE9JbTJmM1BQMDVZWThlYmpRZmh4cGJCYWZTcjZnUk40MDZKQl9jQm9SVDNsMmdGblJmb21tbndQd2FVeGdRZVBKRUlZZWZLRC1BTWoyMm9NSnhqYVNXNXVRT0Y4SXBWbzNDZ0Y0Q3VYNnJIamM4bThQaTRjNU44Vl9SZkVqbkpqZHNIX1UyMTg4QVJYdzBP?oc=5" target="_blank">LabCentral 238 Opens with Focus on Scale-Up Bio-Manufacturing</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment Committee
Business Wireworld

MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment Committee

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQQ0xfWFd2MlFuSk9hazVfUWc2X3ltZGRvN0VEUlZwM1VfMDRVSGJMVmh6M2JtLXJpT1paamEtVzhLa0J5MXVZQ2t1MVluR0psMWNXZlhDQmpQenl2dlRXRmd1aVBTVnVlZHNtQ2JzNTJ3NW5KcFhObzFaSk5yVEZ4QjNsWHdzUUhEbFk0eG1IQ1dOeFFZOUYzMElGc2hVNWNtU0NvRm5LcW0tQW1FZ05QX3A5Vl9FazVsUEFjUllMTFJWVGJ4aTlKVGkxTGpWN3prd1RJMjBTRzNDOVdnTVM5ZF9DWQ?oc=5" target="_blank">MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment Committee</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Art Levin trades the C-suite for pair of roles at Avidity; Ex-Merck CEO Ken Frazier to chair another company
Endpoints Newstech

Art Levin trades the C-suite for pair of roles at Avidity; Ex-Merck CEO Ken Frazier to chair another company

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOREl1VkVKUjBIX0xCd0pKUVZ1X2txbWVsYl90VHk1V2R0UjBtTmxLNFV1ck9Jbi1DREtWQW5mLXZiQ1NZU2o4WndiQXRuX3dXa0JmV015OVNNVmpTUEtyWml2NEpNc0o5bmFnZU1UQmxVZjc2MmtldDA1UENKeXpBS1JMN1FFZjRQNk5YX0tmTWRvOU5GcUN6ZEp0azdjZHRqWnZQZTFUS1FPY3pUd2xYaGZoLUg1bDZnVlNmMU1BRVdIcnFkNjlsR0F4aw?oc=5" target="_blank">Art Levin trades the C-suite for pair of roles at Avidity; Ex-Merck CEO Ken Frazier to chair another company</a>  <font color="#6f6f6f">Endpoints News</font>

Read Full StoryMore like this
Neuroscience legend Steve Paul retires; Exclusive: GSK hires ex-Innate Pharma CEO for new position
Endpoints Newsscience

Neuroscience legend Steve Paul retires; Exclusive: GSK hires ex-Innate Pharma CEO for new position

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNMEk1OFdxc1lTMHo1RXdZTkhGbG1OUlBTRkpjTVB4YjZNVFRNSE5yelZ1c3Z4QUFORTkzZ1piTFl4cTlCVGZnc0Q2SnZQQVQ4bWZkRmtZRmU4N1F3SXpNMkl1U29VVS02Y3EzWWVOQnRaX1lXQzJHalNMaUFoT3pSTEpFRkpFcnRZaTZxZFo3bHpFQ3pWbEtBZjMyWnFVQ1hqUU5sLU1SbW1pWW9xMzhLSHJyeUxmYmhPSnJqYQ?oc=5" target="_blank">Neuroscience legend Steve Paul retires; Exclusive: GSK hires ex-Innate Pharma CEO for new position</a>  <font color="#6f6f6f">Endpoints News</font>

Read Full StoryMore like this
"NextPoint Therapeutics An" — Live Google News Trends & Headlines